80828-26-8

Basic information

• Product Name: Benzenebutanoicacid,-[[(1S)-1-carboxyethyl]amino]-,monoethylester,hydrochloride,(S)-(9CI)
• Synonyms: Benzenebutanoicacid,-[[(1S)-1-carboxyethyl]amino]-,monoethylester,hydrochloride,(S)-(9CI);Benzenebutanoic acid,-[[(1S)-1-carboxyethyl]amino]-, monoethyl ester, hydrochloride, (S)-;(aS)-a-[[(1S)-1-Carboxyethyl]amino]benzenebutanoic acid 1-ethyl ester hydrochloride
• CAS NO: 80828-26-8
• Molecular Formula: C₁₅H₂₁NO₄*ClH
• Molecular Weight: 315.79
• Mol File: 80828-26-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenebutanoicacid,-[[(1S)-1-carboxyethyl]amino]-,monoethylester,hydrochloride,(S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanoicacid,-[[(1S)-1-carboxyethyl]amino]-,monoethylester,hydrochloride,(S)-(9CI)(80828-26-8)
• EPA Substance Registry System: Benzenebutanoicacid,-[[(1S)-1-carboxyethyl]amino]-,monoethylester,hydrochloride,(S)-(9CI)(80828-26-8)

Safety Data

• Hazardous Substances Data: 80828-26-8(Hazardous Substances Data)

Usage

General Description

Benzenebutanoic acid, -[[(1S)-1-carboxyethyl]amino]-, monoethylester, hydrochloride, (S)-(9CI) is a chemical compound that is used as a pharmaceutical intermediate. It is a monoethylester of a particular type of benzenebutanoic acid, which is a derivative of butanoic acid. The compound is in the form of a hydrochloride salt and exists in its (S) configuration. It is commonly used in the synthesis of various pharmaceutical drugs and is considered an important building block in the production of medicinal compounds.

Upstream product

• 80828-38-2 N-<(S)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 64920-29-2 2-oxo-4-phenylbutanoic acid ethyl ester 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 

Downstream Products

• 108428-39-3 N--L-alanyl>-L-proline tert butyl ester 
• 82586-54-7 quinapril benzyl ester 
• 103733-35-3 <3S-<2>,3R*>-2-<2-<<1-(ethoxycarbonyl)-3-phenylpropyl>amino>-1-oxopropyl>-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, ethyl ester 
• 83435-61-4 N-(2,3-dihydro-1H-inden-2-yl)-N--L-alanyl>-glycine t-butyl ester 
• 82586-56-9 tert-butyl (S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 103733-40-0 tert-butyl (S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 82637-57-8 <3S-<2>,3R*>-2-<2-<<1-(ethoxycarbonyl)-3-phenylpropyl>amino>-1-oxopropyl>-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, phenylmethyl ester 
• 85441-61-8 quinapril 
• 103733-49-9 <3S-<2(R*),3α,11aβ>>-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-α-(2-phenylethyl)-2H-pyrazino<1,2-b>isoquinoline-2-acetic acid, ethyl ester 
• 103775-08-2 (S)-2-[(S)-2-((S)-1-Carboxy-3-phenyl-propylamino)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid tert-butyl ester 
• 103833-16-5 Quinapril 
• 83059-56-7 (S)-2-[(S)-2-((S)-1-Ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-2-aza-bicyclo[2.2.2]octane-3-carboxylic acid 
• 76095-16-4 Amprace 
• 75847-73-3 enalapril 

Relevant articles and documents

CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME

A novel crystalline form of quinapril hydrochloride of formula (I). An amorphous form of quinapril hydrochloride substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications formed from the said novel crystalline form of quinapril hydrochloride of formula (I). The crystalline quinapril hydrochloride is in the form nitroalkane solvate in which the nitroalkane is nitromethane, nitroethane and nitropropane. Each such nitroalkane solvate having particular characteristic X- ray diffraction patterns. A process for preparation of amorphous from of quinapril hydrochloride, substantially free of impurities, specially diketopiperazine compound, and conforming to pharmacopoeial specifications, using the novel crystalline quinapril hydrochloride as an intermediate. The process involves obtaining free base compound of formula (V) by adjusting the pH of a solution of the benzyl ester maleate salt of quinapril of formula (V) between 7.5-8.5 in a mixture of water and an organic solvent; catalytic hydrogenation of this compound (V) in an alcoholic solvent in the presence of concentrated hydrochloric acid or hydrogen chloride dissolved in an alcoholic solvent and in the presence of catalytic amounts of Pd/C to obtain a residue containing formula (I); crystallization of the said residue by evaporating the alcoholic solvent from a nitroalkane solvent to give crystalline quinapril hydrochloride, associated with a solvate of the nitroalkane solvent, and drying the crystalline quinapril hydrochloride nitroalkane solvate at a temperature between 40°C and 45°C under vacuum to give amorphous quinapril hydrochloride of formula (I).